0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV1775.00%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier27DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.53Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Organovo Holdings Stock Discussion
Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting
Organovo Holdings (NASDAQ:ONVO)presented Phase 2 clinical trial results for FXR314 at The Liver Meeting. The study involved 214 MASH patients randomized to receive 3mg, 6mg FXR314, or placebo. The drug demonstrated statistically significant liver fat reduction from baseline: 22.8% (3mg) and 17.5% (6mg) versus 6.1% placebo. Notably, >30% MRI-PDFF reduction was ac...
Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
Organovo Holdings (Nasdaq: ONVO) announces that its lead clinical stage drug, FXR314, will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, scheduled for November 17, 2024, will be del...
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis...
NEWS
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
In a significant step forward for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH), Organovo Holdings Inc. has announced positive Phase 2 trial results for its experimental drug, FXR314. This development marks a pivotal moment in the fight against MASH, a severe form of fatty liver disease that poses a su...
$Organovo Holdings (ONVO.US)$ huge opportunity 💯💯🔥💯🏆🏆🆙🆙💴🆙🏆🏆💯💯🔥🔥🔥🔥🔥🔥🔥🔥🔥🔥
$Organovo Holdings (ONVO.US)$ buy💯💯🔥💯🏆🏆💴🆙🆙🆙🆙
$Organovo Holdings (ONVO.US)$ buy 🔥💯💯🏆🏆💯💯🔥🔥🔥🔥🔥🔥🔥
$Organovo Holdings (ONVO.US)$ buy
No comment yet